Efficacy of superior hypogastric plexus injection with Botulinum toxin type A in chronic pelvic pain with endometriosis

Status

Unknown

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250321001

Enrollment

Registered

2025-03-21

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pelvic pain in endometriosis botulinum toxin A, superior hypogastric plexus, endometriosis, chronic pelvic pain

Interventions

Superior hypogastric plexus injection under fluoroscopic guidance with botulinum toxin A 100 units.

Experimental Drug

Botulinum toxin A

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Female patients aged 18-50 years. 2.Patients diagnosed with chronic lower abdominal pain lasting at least 3 months due to endometriosis, including: 2.1 Diagnosed with endometriosis based on symptoms (dysmenorrhea, pain between menstrual cycles, pelvic pain during intercourse, pain in the rectal area during bowel movements), physical examination (retroverted uterus, masses on the adnexa, lesions on the posterior uterus or in the pelvis from a digital rectal exam), and imaging (transvaginal or transrectal ultrasound or MRI showing ovarian endometrioma or deep endometriosis). 2.2 Diagnosed with endometriosis through surgery (diagnostic laparoscopy) and/or confirmed by biopsy with pathological examination. 3. Able to attend follow-up appointments for up to 3 months until the end of the study

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with chronic lower abdominal pain due to other causes, such as chronic pelvic inflammatory disease, irritable bowel syndrome, urinary issues, or cancer-related pain. 2.Patients with uncontrolled psychiatric disorders. 3.Patients unable to lie face down. 4.Patients allergic to Botulinum Toxin Type A. 5.Patients who have undergone other pain-relieving procedures within the past month. 6.Patients who have received Botulinum Toxin injections in any part of the body within the past 6 months. 7.Patients with abnormal blood clotting disorders.

Design outcomes

Primary

Measure	Time frame
pain intensity at 12 months after intervention numeric rating score	—

Secondary

Measure	Time frame
Quality of life at 12 months after intervention WHOQOL-BRIF(WHO Quality of life-BRIF)	—

Countries

Thailand

Contacts

Public ContactKanita Kositanurit

Chulalongkorn university

kanita.kosi@gmail.com0841135343

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026